Summary Antigenic modulation of major histocompatibility and tumour associated antigens was observed in neoplastic cells obtained from patients with pleural and abdominal effusions of breast and ovary carcinomas following a single intracavitary dose of 18 x 106 U recombinant IFN-a. This regimen resulted in antigenic modulation in seven out of 11 tested cases, suggesting a potential, although limited, responsiveness of at least a fraction of breast and ovary carcinoma cells to in situ biomodification with IFN-a. Clinical trials with IFN-a have shown that the use of this biomodifier is justified only in the treatment of a limited number of hematologic malignancies, still remaining of little use in the control of solid tumors (Goldstein & Laszlo, 1986 (Gamliel et al., 1990) .
In the present report, surface expression of 11 independent major histocompatibility complex (MHC) and tumour associated antigens (TAAs), has been assessed prior to and following IFN-a (Giacomini et al., 1990) .
Although general agreement exists that a 24 h IFN-a treatment is capable of inducing only a suboptimal antigenic modulation of most surface antigens (Greiner et al., 1985; Giacomini et al., 1990 and 1991) , longer intervals between IFN-. administration and testing of antigenic modulation were not considered, since IFN-o has a relatively short (3-6 h) halflife in the bloodstream (Goldstein & Laszlo, 1986) , and causes a readily reversible upregulation of class I MHC antigens in in vivo exposed perypheral blood mononuclear cells (Giacomini et al., 1991 Even in the lack of more detailed informations about the type and relevance of the factors underlying this low response, the present results demonstrate that tumour cells can be modified by IFN-a in vivo. Thus, they extend to an IFN-a/neoplastic effusion model previous observations in other systems (Gamliel et al., 1990; Schiller et al., 1990; Allavena et al., 1990; Giacomini et al., 1991) , and rule out the possibility of a state of absolute refractoriness of cancer cells to in vivo biomodification with the IFNs.
Clearly, a correlation between antigenic modulation and therapeutic efficacy of IFN-x could not be established on the basis of the present data. This, however, was not the main purpose of our testing, since the function of most tumour associated antigens is unknown, and probably unrelated to the induction of antitumour effects by the IFNs. For this reason, the identification of markers of clinical response to the IFNs will likely require the development of ad hoc reagents.
